source
- Regeneron secures first FDA approval for gene therapy treating rare inherited hearing lossRegeneron announced that the U.S. Food and Drug Administration has approved its gene-based treatment Otarmeni, marking the first approval of a therapy for inherited hearing loss. The therapy is de…
- FDA approves Regeneron’s Otarmeni gene therapy for rare inherited hearing lossThe FDA has approved Otarmeni, a gene therapy from Regeneron, marking the first therapy cleared under the agency’s national priority voucher program and will be provided to eligible patients at no…